Parkman Healthcare Partners’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Parkman Healthcare Partners’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,360	Closed	-$344K	–	103
2025 Q1	$344K	Buy	4,360 +1,301	+43%	+$160K	0.04%	89
2024 Q4	$512K	Sell	3,059 -1,000	-25%	-$131K	0.07%	88
2024 Q3	$382K	Sell	4,059 -2,845	-41%	-$270K	0.05%	91
2024 Q2	$680K	Sell	6,904 -7,025	-50%	-$876K	0.09%	84
2024 Q1	$2.14M	Hold	13,929	–	–	0.26%	83
2023 Q4	$1.62M	Buy	+13,929	New	+$2.17M	0.23%	73
2020 Q2	–	Sell	-113	Closed	-$1.09M	–	85
2020 Q1	$1.09M	Buy	+113	New	+$1.77M	0.5%	52

Other funds holding YARW

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Parkman Healthcare Partners's YARW Position: Q2 2025 in Review

Parkman Healthcare Partners sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q2 2025, closing a stake of 4,360 shares — an estimated $344K sold.

Parkman Healthcare Partners first reported a position in YARW in Q1 2020 and held it in 7 quarters. The position peaked at $2.14M in Q1 2024. 44 funds tracked by Wall St. Rank hold YARW as of Q2 2025.

Parkman Healthcare Partners reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
Parkman Healthcare Partners sold 4,360 Yarrow Bioscience, Inc. Common Stock shares in Q2 2025, an estimated $344K.
Parkman Healthcare Partners first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
Parkman Healthcare Partners's Yarrow Bioscience, Inc. Common Stock position peaked at $2.14M in Q1 2024.
44 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q2 2025.

Based on Parkman Healthcare Partners's 13F filing for Q2 2025, filed 14 Aug 2025.